VIRX Viracta Therapeutics Inc

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Company’s Management will participate in upcoming investor conferences in November.

Details on the conferences can be found below:

Stifel 2023 Healthcare Conference Presentation Date: Wednesday, November 15, 2023         Presentation Time: 10:20 – 10:50 AM ET         

Piper Sandler 35th Annual Healthcare Conference Presentation Date: Tuesday, November 28, 2023        Presentation Time: 12:10 – 12:30 PM ET        

6th Annual Evercore ISI HealthCONx Conference Presentation Date: Wednesday, November 29, 2023        Presentation Time: 3:25 – 3:45 PM ET         

A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" and archived for 90 days.

About Viracta Therapeutics, Inc.Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed or refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of patients with recurrent or metastatic EBV+ nasopharyngeal carcinoma and other advanced EBV+ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:Ashleigh BarretoHead of Investor Relations & Corporate CommunicationsViracta Therapeutics, Inc.abarreto@viracta.com

SOURCE Viracta Therapeutics, Inc.